# Rafael Holdings, Inc.: overview RFL · NYSE · CIK 1713863 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jul 31 Pages: [Overview](/companies/rfl.md) · [Financials](/companies/rfl/financials.md) · [Filings](/companies/rfl/filings.md) · [Insiders](/companies/rfl/insiders.md) Latest reported revenue: [$179.0k](/filings/0001213900-26-067560.md) for Q3 FY2026, three months to 2026-04-30, from the 10-Q filed Jun 11, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-067560). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-07-31) | Q1 FY2025 (2024-10-31) | Q2 FY2025 (2025-01-31) | Q3 FY2025 (2025-04-30) | Q4 FY2025 (2025-07-31) | Q1 FY2026 (2025-10-31) | Q2 FY2026 (2026-01-31) | Q3 FY2026 (2026-04-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2 d](/filings/0001213900-25-103549.md) | [0.1](/filings/0001213900-25-120897.md) | [0.1](/filings/0001213900-26-028348.md) | [0.4](/filings/0001213900-26-067560.md) | [(0.5) d](/filings/0001213900-25-103549.md) | [0.2](/filings/0001213900-25-120897.md) | [0.2](/filings/0001213900-26-028348.md) | [0.2](/filings/0001213900-26-067560.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2330.3%) d](/filings/0001213900-25-103549.md) | [(3003.1%)](/filings/0001213900-25-120897.md) | [(8622.1%)](/filings/0001213900-26-028348.md) | [(1633.4%)](/filings/0001213900-26-067560.md) | [2376.7% d](/filings/0001213900-25-103549.md) | [(4225.4%)](/filings/0001213900-25-120897.md) | [(3154.0%)](/filings/0001213900-26-028348.md) | [(3838.0%)](/filings/0001213900-26-067560.md) | | Net margin | % | [(2707.9%) d](/filings/0001213900-25-103549.md) | [(7035.9%)](/filings/0001213900-25-120897.md) | [(6027.3%)](/filings/0001213900-26-028348.md) | [(1320.2%)](/filings/0001213900-26-067560.md) | [54.0% d](/filings/0001213900-25-103549.md) | [(4090.0%)](/filings/0001213900-25-120897.md) | [(3041.2%)](/filings/0001213900-26-028348.md) | [(2360.9%)](/filings/0001213900-26-067560.md) | | Diluted EPS | $ per share | not reported | [(0.37)](/filings/0001213900-25-120897.md) | [(0.19)](/filings/0001213900-26-028348.md) | [(0.19)](/filings/0001213900-26-067560.md) | not reported | [(0.19)](/filings/0001213900-25-120897.md) | [(0.13)](/filings/0001213900-26-028348.md) | [(0.08)](/filings/0001213900-26-067560.md) | | Free cash flow | $m | [(2.9) d](/filings/0001213900-25-103549.md) | [(3.0)](/filings/0001213900-25-120897.md) | [(2.3) d](/filings/0001213900-26-028348.md) | [(3.2) d](/filings/0001213900-26-067560.md) | [(10.4) d](/filings/0001213900-25-103549.md) | not reported | not reported | [(7.3) d](/filings/0001213900-26-067560.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-07-31) | FY2022 (2022-07-31) | FY2023 (2023-07-31) | FY2024 (2024-07-31) | FY2025 (2025-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.8](/filings/0001213900-22-067711.md) | [0.4](/filings/0001213900-23-081589.md) | [0.3](/filings/0001213900-24-110663.md) | [0.6](/filings/0001213900-25-103549.md) | [0.0](/filings/0001213900-25-103549.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(3516.1%)](/filings/0001213900-22-067711.md) | [(14750.5%)](/filings/0001213900-23-081589.md) | [(5391.8%)](/filings/0001213900-24-110663.md) | [(16111.0%)](/filings/0001213900-25-103549.md) | [(97196.7%)](/filings/0001213900-25-103549.md) | | Net margin | % | [(2875.4%)](/filings/0001213900-22-067711.md) | [(30404.4%)](/filings/0001213900-23-081589.md) | [(672.4%)](/filings/0001213900-24-110663.md) | [(5401.9%)](/filings/0001213900-25-103549.md) | [(101733.3%)](/filings/0001213900-25-103549.md) | | Diluted EPS | $ per share | [(1.49)](/filings/0001213900-22-067711.md) | [(6.31)](/filings/0001213900-23-081589.md) | [(0.08)](/filings/0001213900-24-110663.md) | [(1.45)](/filings/0001213900-25-103549.md) | [(1.04)](/filings/0001213900-25-103549.md) | | Free cash flow | $m | [(15.8)](/filings/0001213900-22-067711.md) | [(26.1)](/filings/0001213900-23-081589.md) | not reported | [(7.9)](/filings/0001213900-25-103549.md) | [(18.9)](/filings/0001213900-25-103549.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rfl/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.5m | 1,365,997 | | Added +106,086 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.4m | 429,879 | | Reduced −12,525 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.3m | 390,068 | | Added +24,450 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $914.7k | 278,910 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $677.4k | 206,521 | | Added +1,566 | | [IEQ CAPITAL, LLC](/funds/1779789.md) | 2026-06-30 | $541.1k | 164,963 | | Reduced −24,997 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $515.8k | 157,270 | | Added +95,100 | | [KAHN BROTHERS GROUP INC](/funds/1039565.md) | 2026-06-30 | $493.6k | 150,493 | | Added +91,936 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $369.7k | 112,720 | | Added +67,675 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $343.1k | 104,600 | Call | Reduced −36,400 | ## Recent filings [All 406 filings](/companies/rfl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 08:16 ET | [8-K](/filings/0001213900-26-113564.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-113564 | | 2026-09-30 | 07:23 ET | [8-K](/filings/0001213900-26-104876.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-104876 | | 2026-07-08 | 16:45 ET | [8-K](/filings/0001213900-26-076411.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-076411 | | 2026-06-11 | 08:17 ET | [10-Q](/filings/0001213900-26-067560.md) | Quarterly report, period 2026-04-30 | 0001213900-26-067560 | | 2026-06-11 | 07:55 ET | [8-K](/filings/0001213900-26-067555.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-067555 | | 2026-06-10 | 07:49 ET | [8-K](/filings/0001213900-26-067083.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-067083 | | 2026-04-22 | 07:21 ET | [8-K](/filings/0001213900-26-046380.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-046380 | | 2026-03-16 | 16:40 ET | [10-Q](/filings/0001213900-26-028348.md) | Quarterly report, period 2026-01-31 | 0001213900-26-028348 | | 2026-03-16 | 16:18 ET | [8-K](/filings/0001213900-26-028311.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-028311 | | 2026-01-12 | 16:29 ET | [8-K](/filings/0001213900-26-003411.md) | 5.07 Shareholder vote results | 0001213900-26-003411 | ## Latest annual report [Form 10-K for the fiscal year ended Jul 31, 2025](/filings/0001213900-25-103549.md), filed Oct 29, 2025. ## Forecast league Q4 FY2026, the quarter ended 2026-07-31, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/620d13d7-e0c9-4046-84e0-0da28d5af99f) ## About the filer - CIK: 1713863 - Tickers: RFL - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 11:36 ET. No prices; not investment advice.